Plegridy (PEG-interferon β-1a) / Biogen  >>  Phase 3
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Plegridy (PEG-interferon β-1a) / Biogen
ADVANCE, NCT00906399 / 2008-006333-27: Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis

Checkmark ECTRIMS 2015: Multiple sclerosis (ADVANCE)
Sep 2015 - Sep 2015: ECTRIMS 2015: Multiple sclerosis (ADVANCE)
Checkmark WCN 2015: Multiple sclerosis (ADVANCE)
Aug 2015 - Aug 2015: WCN 2015: Multiple sclerosis (ADVANCE)
Checkmark CMSC 2015
More
Completed
3
1516
US, Canada, Europe, RoW
BIIB017 (peginterferon beta-1a), PEG IFN ß-1a, PEGylated interferon beta-1a, Plegridy, Placebo
Biogen
Relapsing Multiple Sclerosis
10/12
10/13
NCT01337427: Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis

Withdrawn
3
0
US
BIIB017, PEGylated Interferon beta-1a, PEG IFN β-1a
Johns Hopkins University, Biogen
Relapsing Remitting Multiple Sclerosis
08/13
08/13
NCT01332019 / 2010-024477-39: Long-Term Safety and Efficacy Study of Peginterferon Beta-1a

Checkmark ATTAIN
Apr 2015 - Apr 2015: ATTAIN
Checkmark AAN 2015: Multiple sclerosis (ATTAIN)
Mar 2015 - Mar 2015: AAN 2015: Multiple sclerosis (ATTAIN)
Checkmark ATTAIN
More
Completed
3
1077
US, Canada, Europe, RoW
peginterferon beta-1a, PEGylated Interferon beta-1a, Plegridy, PEG IFN β-1a, BIIB017
Biogen
Relapsing Multiple Sclerosis
10/15
10/15
NCT01939002: Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)

Checkmark ALLOW
Jun 2016 - Jun 2016: ALLOW
Completed
3
251
US
BIIB017, Plegridy, peginterferon beta-1a, PEGylated interferon beta-1a, PEG IFN β-1a, naproxen, naproxen sodium, Aleve, NSAID, long-acting nonsteroidal anti-inflammatory drug
Biogen
Relapsing Multiple Sclerosis
10/15
11/15
ConCorD-19, NCT04552379: The Containing Coronavirus Disease 19 (COVID-19) Trial

Completed
3
1173
RoW
Peginterferon beta-1a, Plegridy
Pontificia Universidad Catolica de Chile, Telethon Kids Institute
SARS-CoV Infection, Interferon, Covid19
05/21
06/21
NCT03870763 / 2018-000516-22: Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Terminated
3
11
Europe, US, RoW
Dimethyl Fumarate, Tecfidera, BG00012, Peginterferon Beta-1a, Plegridy, BIIB017, Placebo
Biogen
Multiple Sclerosis, Relapsing-Remitting
07/22
07/22
NCT03958877 / 2018-003008-38: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Active, not recruiting
3
142
Europe, US, RoW
BIIB017 (peginterferon beta-1a), PLEGRIDY, Interferon beta type 1a, Avonex
Biogen
Multiple Sclerosis, Relapsing-Remitting
05/27
05/27

Download Options